Securities Code: 002262 Securities Abbreviation: Enwei Pharmaceutical Jiangsu Enwei Pharmaceutical Co., Ltd. Announcement No.: 2026-017 Announcement on the Implementation of the 2025 Annual Equity Distribution The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions. Company Statement: The distribution plan implemented this time is consistent with the distribution plan deliberated and approved by the Shareholders' Meeting and its adjustment principles, and the time elapsed since the Shareholders' Meeting deliberated the profit distribution plan does not exceed two months.
1. Matters Regarding the Profit Distribution Plan Deliberated and Approved by the Shareholders' Meeting
- Jiangsu Enwei Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "this Company") held its 2025 Annual Shareholders' Meeting on May 15, 2026, which deliberated and approved the "2025 Profit Distribution Plan". The 2025 profit distribution plan of the Company is as follows: Based on the total share capital of 1,015,786,583 shares as of December 31, 2025, a cash dividend of RMB 4.00 (tax inclusive) will be distributed per 10 shares to all shareholders. The cash dividend for this period is expected to be RMB 406,314,633.20, accounting for 38.43% of the net profit attributable to shareholders of the listed company in 2025. No bonus shares will be issued, nor will the capital reserve be converted into share capital. After the implementation of this profit distribution plan, the undistributed profit retained will be RMB 5,915,057,107.17, which will be carried forward for distribution in subsequent years. If the total share capital of the Company changes before the implementation of the distribution plan after the announcement of the distribution proposal due to reasons such as conversion of convertible bonds, share buybacks, exercise of share options under equity incentives, or new shares issued from refinancing, the base